{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:28:33Z","timestamp":1761895713153},"reference-count":13,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Exp Hematopathol","JCEH"],"published-print":{"date-parts":[[2013]]},"DOI":"10.3960\/jslrt.53.121","type":"journal-article","created":{"date-parts":[[2013,8,30]],"date-time":"2013-08-30T23:14:14Z","timestamp":1377904454000},"page":"121-125","source":"Crossref","is-referenced-by-count":12,"title":["Standard R-CHOP Therapy in Follicular Lymphoma and Diffuse Large B-Cell Lymphoma"],"prefix":"10.3960","volume":"53","author":[{"given":"Naoto","family":"Tomita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Takasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuho","family":"Miyashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eriko","family":"Ogusa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumiko","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiro","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rika","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Koharazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsumichi","family":"Fujimaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimi","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Kuwabara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Motomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Ishigatsubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","unstructured":"1 Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, <I>et al<\/I>.: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone : results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-3732, 2005"},{"key":"2","unstructured":"2 Pfreundschuh M, Tr&uuml;mper L, Osterborg A, Pettengell R, Trneny M, <I>et al<\/I>.: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma : a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379-391, 2006"},{"key":"3","unstructured":"3 Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, <I>et al<\/I>.: Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients : a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 116:2040-2045, 2010"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Siddhartha G, Vijay P: R-CHOP versus R-CVP in the treatment of follicular lymphoma : a meta-analysis and critical appraisal of current literature. J Hematol Oncol 2:14, 2009","DOI":"10.1186\/1756-8722-2-14"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 No authors listed : A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993","DOI":"10.1056\/NEJM199309303291402"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, <I>et al<\/I>.: The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 108:1504-1508, 2006","DOI":"10.1182\/blood-2006-01-013367"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, <I>et al<\/I>.: The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109:1857-1861, 2007","DOI":"10.1182\/blood-2006-08-038257"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Shustik J, Quinn M, Connors JM, Gascoyne RD, Skinnider B, <I>et al<\/I>.: Follicular non-Hodgkin lymphoma grades 3A and 3B have a similar outcome and appear incurable with anthracycline-based therapy. Ann Oncol 22:1164-1169, 2011","DOI":"10.1093\/annonc\/mdq574"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Mounier N, Briere J, Gisselbrecht C, Emile JF, Lederlin P, <I>et al<\/I>.: Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101:4279-4284, 2003","DOI":"10.1182\/blood-2002-11-3442"},{"key":"10","unstructured":"10 Winter JN, Weller EA, Horning SJ, Krajewska M, Variakojis D, <I>et al<\/I>.: Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP : a prospective correlative study. Blood 107:4207-4213, 2006"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Shustik J, Han G, Farinha P, Johnson NA, Ben Neriah S, <I>et al<\/I>.: Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP. Haematologica 95:96-101, 2010","DOI":"10.3324\/haematol.2009.007203"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Watanabe R, Tomita N, Matsumoto C, Hattori Y, Matsuura S, <I>et al<\/I>. The 3q27 and 18q21 translocations for follicular lymphoma and diffuse large B-cell lymphoma in the rituximab era. J Clin Exp Hematop 107-114, 2013","DOI":"10.3960\/jslrt.53.107"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Barrans S, Crouch S, Smith A, Turner K, Owen R, <I>et al<\/I>. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 28:3360-3365, 2010","DOI":"10.1200\/JCO.2009.26.3947"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T19:46:26Z","timestamp":1621539986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/53\/2\/53_121\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.53.121","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}